Li Yang1, Qu Xiufen, Sun Shuqin, Yu Yang, Song Ying, Yu Yanwei, Feng Wei, Yin Dechun. 1. Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, No. 23 Youzheng Street, Nangang District, Harbin City, Heilongjiang Province, People's Republic of China.
Abstract
PURPOSE: It has been reported that elevation of asymmetric dimethylarginine (ADMA) concentration is involved in atrial fibrillation (AF) process. The purpose of this study was to determine whether ADMA concentration is related to recurrences of AF after catheter ablation. METHODS: A total of one hundred and thirty-eight patients with persistent AF (49.91 ± 7.23 years), but without known heart disease, who underwent successful mapping and catheter ablation were included. Serum ADMA levels were measured 1 day before the catheter ablation. RESULTS: After a mean follow-up period of 285 days (range, 98-651 days), 80 (58%) patients underwent the AF recurrence. Comparing with no AF recurrence group, the serum ADMA concentration, left atrial diameter, and persistent duration of AF in patients with AF recurrence group were significantly increased. Left atrial diameter, persistent duration of AF, and the number of non-pulmonary vein ectopy ablation were increased when serum ADMA concentration was elevated. In addition, AF recurrences were significantly increased when serum ADMA concentration was elevated. A multivariable Cox regression analysis demonstrated that the elevated ADMA concentration [hazard ration (95% CI), 4.59 (1.81-11.62); P = 0.001], the left atrial diameter [1.35 (1.18-1.55), P < 0.001], and the number of non-pulmonary vein ectopy ablation [1.94 (1.18-3.18), P = 0.009] were independent factors associated with the AF recurrence after catheter ablation. CONCLUSIONS: This study demonstrated that (1) serum ADMA concentrations were associated with non-PV ectopies and (2) increased serum ADMA concentrations were associated with higher rate of AF recurrence after catheter ablation in patients with persistent AF, supporting our hypothesis that ADMA might participate in the process of atrial remodeling.
PURPOSE: It has been reported that elevation of asymmetric dimethylarginine (ADMA) concentration is involved in atrial fibrillation (AF) process. The purpose of this study was to determine whether ADMA concentration is related to recurrences of AF after catheter ablation. METHODS: A total of one hundred and thirty-eight patients with persistent AF (49.91 ± 7.23 years), but without known heart disease, who underwent successful mapping and catheter ablation were included. Serum ADMA levels were measured 1 day before the catheter ablation. RESULTS: After a mean follow-up period of 285 days (range, 98-651 days), 80 (58%) patients underwent the AF recurrence. Comparing with no AF recurrence group, the serum ADMA concentration, left atrial diameter, and persistent duration of AF in patients with AF recurrence group were significantly increased. Left atrial diameter, persistent duration of AF, and the number of non-pulmonary vein ectopy ablation were increased when serum ADMA concentration was elevated. In addition, AF recurrences were significantly increased when serum ADMA concentration was elevated. A multivariable Cox regression analysis demonstrated that the elevated ADMA concentration [hazard ration (95% CI), 4.59 (1.81-11.62); P = 0.001], the left atrial diameter [1.35 (1.18-1.55), P < 0.001], and the number of non-pulmonary vein ectopy ablation [1.94 (1.18-3.18), P = 0.009] were independent factors associated with the AF recurrence after catheter ablation. CONCLUSIONS: This study demonstrated that (1) serum ADMA concentrations were associated with non-PV ectopies and (2) increased serum ADMA concentrations were associated with higher rate of AF recurrence after catheter ablation in patients with persistent AF, supporting our hypothesis that ADMA might participate in the process of atrial remodeling.
Authors: M A Allessie; P A Boyden; A J Camm; A G Kléber; M J Lab; M J Legato; M R Rosen; P J Schwartz; P M Spooner; D R Van Wagoner ; A L Waldo Journal: Circulation Date: 2001-02-06 Impact factor: 29.690
Authors: A Natale; E Pisanó; S Beheiry; M Richey; F Leonelli; R Fanelli; M Potenza; G Tomassoni Journal: Am J Cardiol Date: 2000-06-01 Impact factor: 2.778
Authors: Hugh Calkins; Josep Brugada; Douglas L Packer; Riccardo Cappato; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; David E Haines; Michel Haissaguerre; Yoshito Iesaka; Warren Jackman; Pierre Jais; Hans Kottkamp; Karl Heinz Kuck; Bruce D Lindsay; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Andrea Natale; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Jeremy N Ruskin; Richard J Shemin Journal: Heart Rhythm Date: 2007-04-30 Impact factor: 6.343
Authors: Antonios Kourliouros; Irina Savelieva; Anatoli Kiotsekoglou; Marjan Jahangiri; John Camm Journal: Am Heart J Date: 2008-12-24 Impact factor: 4.749
Authors: Ilkka Seppälä; Marcus E Kleber; Steve Bevan; Leo-Pekka Lyytikäinen; Niku Oksala; Jussi A Hernesniemi; Kari-Matti Mäkelä; Peter M Rothwell; Cathie Sudlow; Martin Dichgans; Nina Mononen; Efthymia Vlachopoulou; Juha Sinisalo; Graciela E Delgado; Reijo Laaksonen; Tuomas Koskinen; Hubert Scharnagl; Mika Kähönen; Hugh S Markus; Winfried März; Terho Lehtimäki Journal: Sci Rep Date: 2016-03-17 Impact factor: 4.379